

November 4, 2024

**Notice of Price Adjustment to 340B Covered Entities That Purchased NORVIR® (ritonavir)
from August 1, 2024 through October 31, 2024**

AbbVie Inc. (“AbbVie”) is offering refunds to certain 340B covered entities that purchased NORVIR® (ritonavir) (“NORVIR”) during the period August 1, 2024 through October 31, 2024 (the “Refund Period”).

NORVIR no longer maintains an orphan designation. Accordingly, a 340B covered entity that meets the following criteria may be eligible for a refund for certain purchases of NORVIR during the Refund Period:

1. Was active in Health Resources and Services Administration’s (“HRSA”) Office of Pharmacy Affairs Information System (“OPAIS”) during the Refund Period as one of the following covered entity types: (A) rural referral center (eligible pursuant to 42 U.S.C. § 256b(4)(O)), (B) sole community hospital (eligible pursuant to 42 U.S.C. § 256b(4)(O)), (C) critical access hospital (eligible pursuant to 42 U.S.C. § 256b(4)(N)), or (D) free-standing cancer hospital (eligible pursuant to 42 U.S.C. § 256b(4)(M)); and
2. Purchased NORVIR at a commercial price rather than the applicable 340B price during the Refund Period.

Refund Request Process:

AbbVie requests that any eligible covered entity that satisfies the criteria set forth above and that made purchases that otherwise would have been eligible for 340B pricing at the time of purchase submit a refund request to the wholesaler from which it purchased NORVIR.

All pricing adjustments will be handled by the wholesaler from which the eligible covered entity purchased NORVIR. Eligible covered entities should submit all requests to their wholesaler by October 31, 2025.

If you have any questions or require assistance with respect to a refund request, please contact your wholesaler. You may also contact AbbVie at 340bcommunications@abbvie.com with subject line: “NORVIR Refund Request.”

AbbVie asked the HRSA Office of Pharmacy Affairs (“OPA”) to post this Notice on OPA’s website to give affected eligible covered entities the opportunity to request refunds.

* * *

All eligible covered entities may purchase NORVIR at the 340B ceiling price through their wholesaler as of November 1, 2024.